Major advances have been reached recently in the knowledge of acute lymphoblastic leukaemia (ALL), including the comprehensive description of B-cell precursor and T-cell ALL genomic landscapes, identification of new potentially druggable disease subsets and discovery of predisposing preleukemic events. During the same period of time, progresses have been accomplished in the management of children and adults with ALL, thanks to routine monitoring of measurable residual disease (MRD), administration of intensi ed risk-adapted chemotherapy, introduction of targeted therapies and antibodies, followed by the remarkable efficacy of antibody-drug conjugates (ADCs), bi specific T-cell engager antibodies (BiTEs) and manufactured chimeric antigen receptor (CAR) T-cells.
This intense research activity has made ALL a fascinating disease, allowing major improvements in patients’ outcome, while providing important proofs of concept for the treatment of cancer in general.
The 1st ESH Translational Conference on ALL is designed to provide time and multiple opportunities for discussions and interactions with internationally recognised physicians and scientists in the field.
